Cargando…
Biochemical and pathological changes result from mutated Caveolin-3 in muscle
BACKGROUND: Caveolin-3 (CAV3) is a muscle-specific protein localized to the sarcolemma. It was suggested that CAV3 is involved in the connection between the extracellular matrix (ECM) and the cytoskeleton. Caveolinopathies often go along with increased CK levels indicative of sarcolemmal damage. So...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6114045/ https://www.ncbi.nlm.nih.gov/pubmed/30153853 http://dx.doi.org/10.1186/s13395-018-0173-y |
_version_ | 1783351123287998464 |
---|---|
author | González Coraspe, José Andrés Weis, Joachim Anderson, Mary E. Münchberg, Ute Lorenz, Kristina Buchkremer, Stephan Carr, Stephanie Zahedi, René Peiman Brauers, Eva Michels, Hannah Sunada, Yoshihide Lochmüller, Hanns Campbell, Kevin P. Freier, Erik Hathazi, Denisa Roos, Andreas |
author_facet | González Coraspe, José Andrés Weis, Joachim Anderson, Mary E. Münchberg, Ute Lorenz, Kristina Buchkremer, Stephan Carr, Stephanie Zahedi, René Peiman Brauers, Eva Michels, Hannah Sunada, Yoshihide Lochmüller, Hanns Campbell, Kevin P. Freier, Erik Hathazi, Denisa Roos, Andreas |
author_sort | González Coraspe, José Andrés |
collection | PubMed |
description | BACKGROUND: Caveolin-3 (CAV3) is a muscle-specific protein localized to the sarcolemma. It was suggested that CAV3 is involved in the connection between the extracellular matrix (ECM) and the cytoskeleton. Caveolinopathies often go along with increased CK levels indicative of sarcolemmal damage. So far, more than 40 dominant pathogenic mutations have been described leading to several phenotypes many of which are associated with a mis-localization of the mutant protein to the Golgi. Golgi retention and endoplasmic reticulum (ER) stress has been demonstrated for the CAV3 p.P104L mutation, but further downstream pathophysiological consequences remained elusive so far. METHODS: We utilized a transgenic (p.P104L mutant) mouse model and performed proteomic profiling along with immunoprecipitation, immunofluorescence and immunoblot examinations (including examination of α-dystroglycan glycosylation), and morphological studies (electron and coherent anti-Stokes Raman scattering (CARS) microscopy) in a systematic investigation of molecular and subcellular events in p.P104L caveolinopathy. RESULTS: Our electron and CARS microscopic as well as immunological studies revealed Golgi and ER proliferations along with a build-up of protein aggregates further characterized by immunoprecipitation and subsequent mass spectrometry. Molecular characterization these aggregates showed affection of mitochondrial and cytoskeletal proteins which accords with our ultra-structural findings. Additional global proteomic profiling revealed vulnerability of 120 proteins in diseased quadriceps muscle supporting our previous findings and providing more general insights into the underlying pathophysiology. Moreover, our data suggested that further DGC components are altered by the perturbed protein processing machinery but are not prone to form aggregates whereas other sarcolemmal proteins are ubiquitinated or bind to p62. Although the architecture of the ER and Golgi as organelles of protein glycosylation are altered, the glycosylation of α-dystroglycan presented unchanged. CONCLUSIONS: Our combined data classify the p.P104 caveolinopathy as an ER-Golgi disorder impairing proper protein processing and leading to aggregate formation pertaining proteins important for mitochondrial function, cytoskeleton, ECM remodeling and sarcolemmal integrity. Glycosylation of sarcolemmal proteins seems to be normal. The new pathophysiological insights might be of relevance for the development of therapeutic strategies for caveolinopathy patients targeting improved protein folding capacity. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13395-018-0173-y) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6114045 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-61140452018-09-04 Biochemical and pathological changes result from mutated Caveolin-3 in muscle González Coraspe, José Andrés Weis, Joachim Anderson, Mary E. Münchberg, Ute Lorenz, Kristina Buchkremer, Stephan Carr, Stephanie Zahedi, René Peiman Brauers, Eva Michels, Hannah Sunada, Yoshihide Lochmüller, Hanns Campbell, Kevin P. Freier, Erik Hathazi, Denisa Roos, Andreas Skelet Muscle Research BACKGROUND: Caveolin-3 (CAV3) is a muscle-specific protein localized to the sarcolemma. It was suggested that CAV3 is involved in the connection between the extracellular matrix (ECM) and the cytoskeleton. Caveolinopathies often go along with increased CK levels indicative of sarcolemmal damage. So far, more than 40 dominant pathogenic mutations have been described leading to several phenotypes many of which are associated with a mis-localization of the mutant protein to the Golgi. Golgi retention and endoplasmic reticulum (ER) stress has been demonstrated for the CAV3 p.P104L mutation, but further downstream pathophysiological consequences remained elusive so far. METHODS: We utilized a transgenic (p.P104L mutant) mouse model and performed proteomic profiling along with immunoprecipitation, immunofluorescence and immunoblot examinations (including examination of α-dystroglycan glycosylation), and morphological studies (electron and coherent anti-Stokes Raman scattering (CARS) microscopy) in a systematic investigation of molecular and subcellular events in p.P104L caveolinopathy. RESULTS: Our electron and CARS microscopic as well as immunological studies revealed Golgi and ER proliferations along with a build-up of protein aggregates further characterized by immunoprecipitation and subsequent mass spectrometry. Molecular characterization these aggregates showed affection of mitochondrial and cytoskeletal proteins which accords with our ultra-structural findings. Additional global proteomic profiling revealed vulnerability of 120 proteins in diseased quadriceps muscle supporting our previous findings and providing more general insights into the underlying pathophysiology. Moreover, our data suggested that further DGC components are altered by the perturbed protein processing machinery but are not prone to form aggregates whereas other sarcolemmal proteins are ubiquitinated or bind to p62. Although the architecture of the ER and Golgi as organelles of protein glycosylation are altered, the glycosylation of α-dystroglycan presented unchanged. CONCLUSIONS: Our combined data classify the p.P104 caveolinopathy as an ER-Golgi disorder impairing proper protein processing and leading to aggregate formation pertaining proteins important for mitochondrial function, cytoskeleton, ECM remodeling and sarcolemmal integrity. Glycosylation of sarcolemmal proteins seems to be normal. The new pathophysiological insights might be of relevance for the development of therapeutic strategies for caveolinopathy patients targeting improved protein folding capacity. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13395-018-0173-y) contains supplementary material, which is available to authorized users. BioMed Central 2018-08-28 /pmc/articles/PMC6114045/ /pubmed/30153853 http://dx.doi.org/10.1186/s13395-018-0173-y Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research González Coraspe, José Andrés Weis, Joachim Anderson, Mary E. Münchberg, Ute Lorenz, Kristina Buchkremer, Stephan Carr, Stephanie Zahedi, René Peiman Brauers, Eva Michels, Hannah Sunada, Yoshihide Lochmüller, Hanns Campbell, Kevin P. Freier, Erik Hathazi, Denisa Roos, Andreas Biochemical and pathological changes result from mutated Caveolin-3 in muscle |
title | Biochemical and pathological changes result from mutated Caveolin-3 in muscle |
title_full | Biochemical and pathological changes result from mutated Caveolin-3 in muscle |
title_fullStr | Biochemical and pathological changes result from mutated Caveolin-3 in muscle |
title_full_unstemmed | Biochemical and pathological changes result from mutated Caveolin-3 in muscle |
title_short | Biochemical and pathological changes result from mutated Caveolin-3 in muscle |
title_sort | biochemical and pathological changes result from mutated caveolin-3 in muscle |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6114045/ https://www.ncbi.nlm.nih.gov/pubmed/30153853 http://dx.doi.org/10.1186/s13395-018-0173-y |
work_keys_str_mv | AT gonzalezcoraspejoseandres biochemicalandpathologicalchangesresultfrommutatedcaveolin3inmuscle AT weisjoachim biochemicalandpathologicalchangesresultfrommutatedcaveolin3inmuscle AT andersonmarye biochemicalandpathologicalchangesresultfrommutatedcaveolin3inmuscle AT munchbergute biochemicalandpathologicalchangesresultfrommutatedcaveolin3inmuscle AT lorenzkristina biochemicalandpathologicalchangesresultfrommutatedcaveolin3inmuscle AT buchkremerstephan biochemicalandpathologicalchangesresultfrommutatedcaveolin3inmuscle AT carrstephanie biochemicalandpathologicalchangesresultfrommutatedcaveolin3inmuscle AT zahedirenepeiman biochemicalandpathologicalchangesresultfrommutatedcaveolin3inmuscle AT brauerseva biochemicalandpathologicalchangesresultfrommutatedcaveolin3inmuscle AT michelshannah biochemicalandpathologicalchangesresultfrommutatedcaveolin3inmuscle AT sunadayoshihide biochemicalandpathologicalchangesresultfrommutatedcaveolin3inmuscle AT lochmullerhanns biochemicalandpathologicalchangesresultfrommutatedcaveolin3inmuscle AT campbellkevinp biochemicalandpathologicalchangesresultfrommutatedcaveolin3inmuscle AT freiererik biochemicalandpathologicalchangesresultfrommutatedcaveolin3inmuscle AT hathazidenisa biochemicalandpathologicalchangesresultfrommutatedcaveolin3inmuscle AT roosandreas biochemicalandpathologicalchangesresultfrommutatedcaveolin3inmuscle |